EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: A brief report on the Australian EPO-TBI clinical trial
- 21 April 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Clinical Neuroscience
- Vol. 76, 5-8
- https://doi.org/10.1016/j.jocn.2020.04.081
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 10 references indexed in Scilit:
- Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational studyThe Lancet Neurology, 2018
- Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical TrialCritical Care Medicine, 2018
- Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI StudyJournal of Neurotrauma, 2018
- A Systematic Review of the Usefulness of Glial Fibrillary Acidic Protein for Predicting Acute Intracranial Lesions following Head TraumaFrontiers in Neurology, 2017
- A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injuryActa Neurochirurgica, 2016
- Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trialThe Lancet, 2015
- Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trialTrials, 2015
- Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain InjuryJAMA, 2014
- GFAP and S100B are biomarkers of traumatic brain injuryNeurology, 2010
- S-100βReflects the Extent of Injury and Outcome, Whereas Neuronal Specific Enolase Is a Better Indicator of Neuroinflammation in Patients With Severe Traumatic Brain InjuryJournal of Neurotrauma, 2001